Michelle M McDonald
Overview
Explore the profile of Michelle M McDonald including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1975
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kumar S, Wang M, Kim A, Center J, McDonald M, Girgis C
J Bone Miner Res
. 2025 Mar;
PMID: 40057981
Denosumab is a highly effective treatment for osteoporosis, and its long-term use is associated with incremental gains in bone mineral density (BMD) and sustained fracture risk reduction. Stopping denosumab, however,...
2.
Buja L, McDonald M, Zhao B, Narula N, Narula J, Barth R
Cardiovasc Pathol
. 2025 Feb;
76:107726.
PMID: 39971218
Context: Ischemic heart disease (IHD) due to coronary atherosclerosis constitutes the leading cause of morbidity and mortality worldwide. This review was undertaken to document the historical basis for our contemporary...
3.
Buja L, McDonald M, Zhao B, Narula N, Narula J, Barth R
Cardiovasc Pathol
. 2025 Feb;
76:107727.
PMID: 39956412
Context: Ischemic heart disease (IHD) due to coronary atherosclerosis constitutes the leading cause of morbidity and mortality worldwide. This review was undertaken to retrospectively analyze the lines of research that...
4.
Kim A, Taylor V, Castro-Martinez A, Dhakal S, Zamerli A, Mohanty S, et al.
J Bone Miner Res
. 2025 Jan;
40(3):413-427.
PMID: 39846954
Rebound bone loss following denosumab discontinuation is an important barrier in the effective long-term treatment of skeletal disorders. This is driven by increased osteoclastic bone resorption following the offset of...
5.
Ramchand S, McDonald M
J Bone Miner Res
. 2025 Jan;
40(3):299-300.
PMID: 39846893
No abstract available.
6.
El-Masri B, Andreasen C, Laursen K, Kofod V, Dahl X, Nielsen M, et al.
Bone Res
. 2024 Oct;
12(1):62.
PMID: 39424806
Denosumab is a monoclonal anti-RANKL antibody that inhibits bone resorption, increases bone mass, and reduces fracture risk. Denosumab discontinuation causes an extensive wave of rebound resorption, but the cellular mechanisms...
7.
Kumar S, Gild M, McDonald M, Kim A, Clifton-Bligh R, Girgis C
Osteoporos Int
. 2024 Aug;
35(10):1871-1872.
PMID: 39120625
No abstract available.
8.
Zhao B, Zaqqa A, McDonald M, Salas de Armas I, Gregoric I, Buja L
Tex Heart Inst J
. 2024 Aug;
51(2).
PMID: 39093814
Primary cardiac angiosarcoma is a rare, aggressive malignancy that commonly metastasizes to various organs. The presenting symptoms are typically nonspecific, so a comprehensive examination is required to confirm the diagnosis...
9.
Kumar S, Gild M, McDonald M, Kim A, Clifton-Bligh R, Girgis C
Osteoporos Int
. 2024 Jun;
35(9):1669-1675.
PMID: 38839655
Purpose/introduction: In patients with severe osteoporosis, the optimal approach for sequential treatment between denosumab and romosozumab has not been established. The ideal strategy would maximise gains in bone mineral density...
10.
Ruiz-Lozano R, Calvo-Gallego J, Pivonka P, McDonald M, Martinez-Reina J
Biomech Model Mechanobiol
. 2024 May;
23(4):1393-1409.
PMID: 38700787
Numerical models of bone remodelling have traditionally been used to perform in silico tests of bone loss in postmenopausal women and also to simulate the response to different drug treatments....